How did Edwards Lifesciences' revenue perform in the third quarter and year-to-date?

Edwards Lifesciences reported robust revenue growth, with net sales increasing by 12.3% to $1.48 billion for the three months ended September 30, 2023, and by 10.8% to $4.47 billion for the nine months ended September 30, 2023. This growth was primarily driven by strong sales in their Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product groups.

What is the company's profitability trend, and are there any significant charges impacting earnings?

The company demonstrated improved profitability, with operating income rising to $418.4 million for the third quarter. Net income attributable to Edwards Lifesciences was $384.9 million for the quarter. However, the nine-month period's results were impacted by a significant $300 million charge related to an intellectual property agreement with Medtronic, which affected year-to-date profitability. Despite this, the company's core operations continue to generate strong earnings.

What is the company's cash flow situation and liquidity?

Edwards Lifesciences maintains a strong financial position. For the first nine months of 2023, net cash provided by operating activities was $759.2 million, indicating healthy cash generation. As of September 30, 2023, the company held $1.41 billion in cash and cash equivalents, and $523.9 million in short-term investments, demonstrating ample liquidity to fund its operations and strategic initiatives.

Are there any significant legal or regulatory matters that investors should be aware of?

The company disclosed an ongoing internal review and investigation into potential violations of the Foreign Corrupt Practices Act (FCPA) in Japan and other markets, which is being conducted with the SEC and DOJ. Additionally, a lawsuit was filed by Aortic Innovations LLC regarding patent infringement claims related to the SAPIEN 3 Ultra product. While management does not believe these matters will have a material adverse effect on the company's overall financial condition, they are subject to uncertainties and cannot be predicted with certainty. There is also a significant ongoing tax dispute with the IRS regarding transfer pricing matters, which could potentially have a material impact on financial statements if resolved unfavorably.

EW 10-Q Quarterly Report Q3 FY2023 — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation reported solid revenue growth in the third quarter and first nine months of 2023, driven primarily by its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. Net sales increased by 12.3% and 10.8% respectively for the three and nine-month periods, indicating strong market demand for their innovative cardiac solutions. Despite global economic uncertainties and prior-year charges, the company demonstrated improved profitability. The company's financial health remains robust, supported by healthy cash flows from operations and a strong liquidity position.

Financial Highlights

50 data points

Beta

Revenue

$1.24B

0.8% Gross Margin

Net Income

$383.70M

0.3% Net Margin

EPS (Diluted)

$0.63

Total Assets

$9.37B

Cash & Equivalents

$1.41B

Free Cash Flow

$356.20M

Financial Statements

Beta

Revenue	$1.24B
Cost of Revenue	$250.60M
Gross Profit	$992.80M
R&D Expenses	$242.80M
SG&A Expenses	$381.90M
Operating Income	$365.90M
Net Income	$383.70M
EPS (Basic)	$0.63
EPS (Diluted)	$0.63
Shares Outstanding (Basic)	607.00M
Shares Outstanding (Diluted)	609.50M

Key Highlights

1Net sales grew 12.3% to $1.48 billion for Q3 2023 and 10.8% to $4.47 billion for the first nine months of 2023, driven by strong performance in TAVR and TMTT products.
2Operating income increased to $418.4 million for Q3 2023, reflecting improved operational efficiency.
3Net income attributable to Edwards Lifesciences Corporation was $384.9 million for Q3 2023, demonstrating strong bottom-line performance.
4The company reported $759.2 million in net cash provided by operating activities for the first nine months of 2023, indicating healthy cash generation.
5Inventories increased to $1.03 billion from $875.5 million at year-end 2022, suggesting strategic build-up to meet demand.
6A significant one-time charge of $300 million for an intellectual property agreement with Medtronic was recognized in the first half of 2023, impacting year-to-date profitability.
7Edwards Lifesciences has a strong liquidity position with $1.41 billion in cash and cash equivalents as of September 30, 2023.

Edwards Lifesciences Corp Quarterly Report for Q3 Ended Sep 30, 2023

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions